Medicinal Chemistry: Hit-to-Lead (H2L) (#2)

Medicinal Chemistry Hit-to-Lead (H2L)

• European Biotech company (Rare disease target)
• Supported with 2 FTEs for 12 months
• Elaboration of existing hits to elucidate SAR
• Rational design to deliver drug-like compounds
• Compounds screened by client (SPR and cell assays)
• >200 compounds prepared over four series
• Highly potent compounds with good ADME properties, clear SAR and in vivo efficacy

Back to main Case Study index